178 related articles for article (PubMed ID: 16959001)
1. Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer.
Yamauchi A; Kontani K; Kihara M; Nishi N; Yokomise H; Hirashima M
Breast J; 2006; 12(5 Suppl 2):S196-200. PubMed ID: 16959001
[TBL] [Abstract][Full Text] [Related]
2. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer.
Irie A; Yamauchi A; Kontani K; Kihara M; Liu D; Shirato Y; Seki M; Nishi N; Nakamura T; Yokomise H; Hirashima M
Clin Cancer Res; 2005 Apr; 11(8):2962-8. PubMed ID: 15837748
[TBL] [Abstract][Full Text] [Related]
3. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 expression is a potent prognostic marker in colorectal cancer.
Endo K; Kohnoe S; Tsujita E; Watanabe A; Nakashima H; Baba H; Maehara Y
Anticancer Res; 2005; 25(4):3117-21. PubMed ID: 16080575
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas.
Shimamura T; Sakamoto M; Ino Y; Shimada K; Kosuge T; Sato Y; Tanaka K; Sekihara H; Hirohashi S
Clin Cancer Res; 2002 Aug; 8(8):2570-5. PubMed ID: 12171885
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
Zhang Z; Yamashita H; Toyama T; Yamamoto Y; Kawasoe T; Iwase H
Clin Cancer Res; 2006 Nov; 12(21):6410-4. PubMed ID: 17085653
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer.
Szoke T; Kayser K; Baumhakel JD; Trojan I; Furak J; Tiszlavicz L; Horvath A; Szluha K; Gabius HJ; Andre S
Oncology; 2005; 69(2):167-74. PubMed ID: 16127288
[TBL] [Abstract][Full Text] [Related]
9. Galectins as markers of aggressiveness of mouse mammary carcinoma: towards a lectin target therapy of human breast cancer.
Moiseeva EV; Rapoport EM; Bovin NV; Miroshnikov AI; Chaadaeva AV; Krasilshschikova MS; Bojenko VK; Bijleveld C; van Dijk JE; Den Otter W
Breast Cancer Res Treat; 2005 Jun; 91(3):227-41. PubMed ID: 15952056
[TBL] [Abstract][Full Text] [Related]
10. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
11. Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells.
Glinsky VV; Huflejt ME; Glinsky GV; Deutscher SL; Quinn TP
Cancer Res; 2000 May; 60(10):2584-8. PubMed ID: 10825125
[TBL] [Abstract][Full Text] [Related]
12. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting.
Nagy N; Legendre H; Engels O; André S; Kaltner H; Wasano K; Zick Y; Pector JC; Decaestecker C; Gabius HJ; Salmon I; Kiss R
Cancer; 2003 Apr; 97(8):1849-58. PubMed ID: 12673710
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of galectin-3 is associated with progression of human breast cancer.
Castronovo V; Van Den Brûle FA; Jackers P; Clausse N; Liu FT; Gillet C; Sobel ME
J Pathol; 1996 May; 179(1):43-8. PubMed ID: 8691344
[TBL] [Abstract][Full Text] [Related]
14. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
16. Survivin expression predicts early recurrence in early-stage breast cancer.
Yamashita S; Masuda Y; Kurizaki T; Haga Y; Murayama T; Ikei S; Kamei M; Takeno S; Kawahara K
Anticancer Res; 2007; 27(4C):2803-8. PubMed ID: 17695451
[TBL] [Abstract][Full Text] [Related]
17. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
[TBL] [Abstract][Full Text] [Related]
18. High-level SLP-2 expression and HER-2/neu protein expression are associated with decreased breast cancer patient survival.
Cao W; Zhang B; Liu Y; Li H; Zhang S; Fu L; Niu Y; Ning L; Cao X; Liu Z; Sun B
Am J Clin Pathol; 2007 Sep; 128(3):430-6. PubMed ID: 17709317
[TBL] [Abstract][Full Text] [Related]
19. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
20. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma.
Honjo Y; Inohara H; Akahani S; Yoshii T; Takenaka Y; Yoshida J; Hattori K; Tomiyama Y; Raz A; Kubo T
Clin Cancer Res; 2000 Dec; 6(12):4635-40. PubMed ID: 11156213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
